The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. District Court for the District of Columbia, urging the court to uphold the Health Resources and Services Administration’s decision to reject Johnson & Johnson’s proposed 340B rebate model in a lawsuit brought by J&J to bar the agency from doing so.

“As the Court evaluates this case, it should bear in mind what Justice Kavanaugh wrote for a unanimous Supreme Court just a few years ago: ‘340B hospitals perform valuable services for low-income and rural communities but have to rely on limited federal funding for support,’” the AHA wrote. “J&J’s rebate policy shrinks that already-limited funding even further, endangering the care that 340B hospitals provide for their patients and communities. If J&J is dissatisfied with 340B law or policy, it can seek change in the political branches. But it cannot take the law into its own hands and then seek judicial permission for its extra-legal actions.”

Others joining the AHA in the Feb. 28 filing were the Children’s Hospital Association, the Association of American Medical Colleges and America’s Essential Hospitals.

Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Headline
The AHA today urged Eli Lilly to abandon its 340B Drug Pricing Program claims-data policy and work with the AHA to develop a functional third-party…
Headline
The AHA again is asking the Health Resources and Services Administration to take action after Eli Lilly warned hospitals that they could lose access to…
Headline
The Washington Post yesterday published a letter to the editor from AHA President and CEO Rick Pollack responding to an April 18 editorial criticizing the 340B…